Stockreport

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation plc - Ordinary Shares  (PRTA) 
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.prothena.com
PDF Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3Novo Nordisk successfully completed a Phase [Read more]